Guilford (GLFD) - Steadily Rising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: SteveG who wrote (78)	8/27/1997 12:34:00 AM
From: Miljenko Zuanic	of 496

Steve: >> But don't these compounds exhibit calcineurin inhibiting effects?<< According to this press release and what is available in literature and in patents, it appears that they do not exhibit immunosuppressive effects: vpharm.com >> BTW, are you affiliated with Vertex?<< Definitely NOT. I do not have position on GLFD or VRTX, but I do follow their neuroimmunophilins projects. Also, I follow many CNS-target bt companies and few make significant portion of my portfolio. Personally, as one who do not like AMGN at all, this is a minus for GLFD regardless the financial part of their agreement. This does not mean that I do not like GLFD NIL development compounds. Contrary, at this point (if you care for my opinion) I am giving advantage to GLFD on neuro-expertise/cells biology, and advantage to VRTX on diversity of the drug candidate and medicinal chemistry/rational drug designee. Regards, mz

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next